Ardea Biosciences
As of the edition of 20 October 2026, Ardea Biosciences runs 3 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Ardea Biosciences was acquired in 2012.
- Ardea Biosciences, Inc.: acquired in 2012
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 1 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lesinurad | Ends 2032 (patent) | 1 |
A route B row is one company at one target.
Where its trials are
- Bones, joints and muscles: 18 trials led
- Inherited and neonatal: 18 trials led
- Nutrition and metabolism: 18 trials led